The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...

We recently published a list of Smart Money Ratings For 20 Most Undervalued Stocks. In this article, we are going to take a ...

Immunovant, Inc. (NASDAQ: IMVT) has announced significant changes to its leadership team and an expansion of its developmental initiatives with the addition of two new indications for its IMVT-1402 ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other ...

In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Other co-authors reported financial relationships with Horizon Therapeutics/Amgen, Immunovant, Kriya Therapeutics, Lassen Therapeutics, Sling Therapeutics, and Tourmaline Bio.

Pete Salzmann, Immunovant’s current CEO and board member, is retiring. Immunovant CFO Renee Barnett is also leaving. Charm Therapeutics is looking for an executive to replace founding CEO Laksh ...